8:00 am
Registration & Networking Coffee

8:25 am Chair’s Opening Remarks

Recent Progress & Advancing Assays for Inflammasome Drug Development

8:30 am Targeting IL-1b Pathway for Cancer Immunotherapy

  • Marc Pelletier Senior Principal Scientist - Translational Immune Oncology, Novartis

Synopsis

Session details to be announced

9:00 am Translational Approaches for the Development of Novel NLRP3 Inhibitors

  • Alan Watt Chief Scientific Officer, NodThera

Synopsis

  • Explore ex vivo stimulated blood assays for early clinical evaluation of pharmacodynamics
  • Use of the D305N NLRP3 mechanistic mouse model for assessment of in vivo target cover
  • Discuss In vivo disease models for PK/PD assessment

9:30 am Panel Discussion: Underpinning the Current Leading Challenges & Gaps in Inflammasome Therapeutic Research

  • Ashley Mansell Head of Translational Sciences, Adiso Therapeutics
  • Marianthi Papakosta Associate Director NeuroInflammation/ Neurodegeneration, Takeda
  • Kate Fitzgerald Professor & Vice Chair, Department of Medicine Division of Innate Immunity, University of Massachusetts Chan Medical School
  • Hao Wu Asa & Patricia Springer Professor, Boston Children’s Hospital & Harvard Medical School

Synopsis

  • Availability of appropriate animal models and patient samples
  • Understanding progress and limitations to current biomarkers
  • Movement into clinical trials and regulatory conversations
  • How/Should we locally target inflammasomes at the sites of inflammation ?
  • Dual/multi- inflammasome inhibition – specificity vs multifactorial inflammation in disease?
  • How to dose a known pharmacological effect/target engagement to specific organs without systemic exposure/immunosuppression

10:00 am Reserved Session for Promega

10:30 am
Speed Networking & Morning Coffee Break

Synopsis

This is your opportunity to network and forge new contacts with fellow Inflammasome enthusiasts in a relaxed environment.

Molecular Underpinnings of Inflammasome Dysregulation to Identify Novel Therapeutic Targets Beyond NLRP3

11:30 am Human NLRP1: Patients, Mutations & Indications

  • Bruno Reversade Professor & Director, Laboratory of Human Genetics & Therapeutics GIS & IMCB, A*STAR

Synopsis

Session details to be announced

12:00 pm The CARD8 Inflammasome in HIV Pathogenesis & Disease Progression

  • Liang Shan Assistant Professor, Washington University School of Medicine

Synopsis

  • Learn how CARD8 is an inflammasome sensor for HIV protease activity
  • Discuss how HIV activates the CARD8 inflammasome to trigger pyroptosis of CD4+ T cells
  • Understand how inhibition of CARD8 activation prevents HIV-induced CD4 loss and disease progression

12:30 pm Understanding the Intersection Between Autophagy, Pyroptosis, Lysosomal Flux & Inflammasome Activation for Inflammasome Research

Synopsis

  • Delving into the science behind oxidative inflammasome and metabolism activation
  • Discussing translational takeaways and questions still needing answers

Advances in Proof-of-Concept Trials in Various Disease Groups for Clinical Relevance in Humans

11:30 am RRx-001, a Small Molecule Anticancer Agent in Phase 3, Protects Against Inflammasome-Driven Diseases

Synopsis

  • Evaluate strategy and execution of drug design and translational development
  • Understanding relevant pathology of disease and most up to date learnings on the inflammasome mechanisms, drug design, and patient population
  • Exploring the latest data, potential biomarkers, challenges, and future directions

12:00 pm Harnessing the Power of AI to Decode the GBA: the Inflammasome Connection

Synopsis

Session details to be announced

12:30 pm Progress in Inflammasome Therapies & Biomarkers in Ageing, COVID & Brain Injury

  • Juan Pablo de Rivero Vaccari Associate Professor of Neurological Surgery & The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine

Synopsis

  • Explore how the inflammasome plays a role in early disease onset in a variety of diseases
  • Review how the early role of the inflammasome in disease renders inflammasome signaling proteins as great biomarkers of early disease diagnosis
  • Discuss how with the current development of therapies intended to directly inhibit the inflammasome, inflammasome signaling proteins have the potential to be great theranostic biomarkers

1:00 pm
Lunch Break

Progress in Inflammasomes Beyond NLRP3

2:00 pm Gasdermin B as a Therapeutic Target for GI-associated Diseases

  • Theresa Pizarro Louis Pillemer Endowed Professor of Experimental Pathology, Case Western Reserve University

Synopsis

The role of gasdermin B (GSDMB) as an executioner of pyroptosis in intestinal epithelial cells is controversial, with emerging evidence supporting its role in alternative activities that go beyond pyroptotic cell death.
Recent findings regarding GSDMB’s function during gastrointestinal (GI) disorders suggest an overall protective role of epithelial-derived GSDMB, promoting pyroptosis of cancer cells, bactericidal processes, and epithelial restitution and wound repair
Several opportunities for controlling GSDMB function exists, and at different levels (e.g., as a consequence of GSDMB polymorphisms, by alternative splicing, and through regulation of its cleavage, among others). We are at the advent of discovery regarding GSDMB’s biology, with recent studies providing important insights into the mechanism(s) of such regulation and its specific roles during health and disease states.

2:30 pm IMM-004 small molecule series that inhibits NLRP3, NLPR1, NLRC4 & AIM2

  • Anil Goyal Chief Executive Officer & Board Director, IMMvention Therapeutix

Synopsis

Session details to be announced

3:00 pm Drug Development Progress in NLRP1

Synopsis

  • Evaluate strategy and execution of drug design and translational development, key learnings from NLRP3, and how to integrate these into your work
  • Understanding relevant mechanistic understanding, and predicted patient population
  • Exploring the latest data, challenges, and future directions

3:30 pm Understanding Phase Separation as a Driver of RNA Virus-Induced Activation of the NLRP6 Inflammasome

  • Hao Wu Asa & Patricia Springer Professor, Boston Children’s Hospital & Harvard Medical School

Synopsis

  • Learn how NLRP6 is an inflammasome sensor highly expressed in the GI tract and the liver
  • Evaluate how dsRNA and lipoteichoic acid are direct ligands of NLRP6
  • Assess how ligand sensing induces NLRP6 phase separation, which in turn promotes inflammasome formation and signaling in vitro and in vivo

Advances in Proof-of-Concept Trials in Various Disease Groups for Clinical Relevance in Humans

2:00 pm From Inflammasome to Mitochondria, Novel Therapies for Neurodegenerative Diseases

  • Bradlee Heckmann Chief Scientific Officer & Asst. Professor, Asha Therapeutics & USF Health Neuroscience Institute

Synopsis

  • Inflammasome activation is a key drive of pathology in multiple neurodegenerative diseases
  • Targeting both inflammasomes and mitochondria prove efficacious in reducing pathology in multiple murine disease models.
  • We have developed a novel, brain-penetrant inhibitor of mitochondrial fragmentation that limits inflammation and reduces Parkinson’s Disease pathology

2:30 pm Progress in Inflammasome Therapies in Neuroinflammatory Disease

  • Richard Gordon Group Leader - Clinical Neuroscience, University of Queensland

Synopsis

Session details to be announced

3:00 pm Identification of a Novel Class of Highly Potent, CNS-Penetrant NLRP3 Specific Inhibitors with Excellent Druglike Physical Features

Synopsis

  • Learn how bioAge’s AI-driven discovery platform, based on analysis of proprietary human aging cohort data, revealed that NLRP3 levels rise with age and are positively correlated with all-cause mortality and cognitive decline
  • Discover how to identify novel NLRP3 inhibitors, BioAge screened billions of molecules in a DNA-encoded library (DEL) for compounds that bind purified NLRP3 protein. Further chemical modifications show how is possible to functionally inhibit the NLRP3 inflammasome in vivo and in vitro with comparable or superior potency relative to publicly known inhibitors
  • Review how the newly identified molecules have novel structures and chemical properties, distinct from those of publicly known NLRP3 inhibitors, with features allowing favorable oral bioavailability and BBB penetration

3:30 pm Regulation of the NLRP3 Inflammasome by Anakinra Treatment in Human Disease

  • Pablo Pelegrin Scientific Deputy Director & Principal Investigator, BioMedical Research Institute of Murcia (IMIB-Arrixaca), University of Murcia

Synopsis

Session details to be announced

4:00 pm
Afternoon Refreshments & Poster Session

Synopsis

This is your opportunity to learn, network and forge new contacts with fellow Inflammasome enthusiasts in a relaxed environment

4:30 pm Roundtable Discussion: Delving & Discussing Learnings & Takeaways

Synopsis

This session will facilitate in-depth discussion between participants in an informal environment to absorb, consolidate, and implement the lessons learned on the following key areas:

  • Disease Selection
  • Preclinical Models
  • Translation into Clinic

5:15 pm
Chair’s Closing Remarks & End of Day One